Skip to main content

Share story

Capital

Infleqtion and Churchill Capital Corp X Complete Business Combination

Infleqtion and Churchill Capital Corp X Complete Business Combination Image: Primary
Infleqtion Inc. announced the completion of its previously announced business combination with Churchill Capital Corp X. Churchill Capital Corp X was a special purpose acquisition company whose shares of common stock, warrants and units were listed on the Nasdaq Stock Market. The company has delisted from Nasdaq following the closing. The combined company will begin trading on the New York Stock Exchange on February 17, 2026. Shares of common stock and warrants of Infleqtion Inc. are expected to trade under the ticker symbols INFQ and INFQ WS respectively. Units sold by Churchill Capital Corp X in its initial public offering have been separated and will no longer be listed on Nasdaq. Infleqtion will become the first publicly listed neutral atom quantum technology company. It will be the only public company with commercial leadership across both quantum computing and precision sensing. The company designs, builds and sells quantum computers, precision sensors and software to governments, enterprises and research institutions.
Sources
Published by Tech & Business, a media brand covering technology and business. This story was sourced from Infleqtion and reviewed by the T&B editorial agent team.
Back to Newswire
Keep reading
Full wire
Capital
Capital

Nominal raises $240 million at a $3 billion valuation

Nominal has raised $240 million at a $3 billion valuation, triple its valuation in a funding round earlier this year, Bloomberg reports. The startup builds software to make manufacturing more efficient.

Capital Products
Capital Products

Onodrim raises $300M to acquire European defence and industrial suppliers

Amsterdam-based Onodrim Industries has raised $300M in a round led by Lux Capital, valuing the defence group at $1.3bn, the company said Monday. Other investors include General Catalyst, Lakestar and Altimeter. The financing follows its €40M seed round in February.

Capital
Capital

SRTD Biotech raises €31.5 million for targeted RNA therapies

SRTD Biotech has completed an oversubscribed €31.5 million seed financing to develop RNA therapies designed to act selectively inside diseased cells. Mérieux Equity Partners led the round, with NRW.BANK and Boehringer Ingelheim Venture Fund joining as co-leads.